J&J reports quarterly loss on $13.6 billion tax charge

Johnson & Johnson reported a quarterly loss due to a $13.6 billion charge related to the new U.S. tax law, but beat adjusted quarterly profit estimate on strong demand for new cancer drugs and gains from its Actelion acquisition.

A number of U.S. companies with sizable international operations are booking huge charges related to the new tax law, which encourages companies to repatriate their offshore earnings.

International operations accounted for nearly a half of J&J`s total fourth-quarter sales of $20.20 billion, which was up 11.5 percent from a year earlier.

TRENDING NOW

Earthquake of magnitude 5.7 strikes Peru's Paracas

RD vs SIP: Where to invest? Know advantages and disadvantages of both

WhatsApp rolls out channel alerts, search messages by date features on Android: Report

Post Office Time Deposit Scheme: Interest up to 7.5%, guaranteed returns, fixed income, preclosure rules, other benefits

Animal vs Sam Bahadur Box Office Collection Day 9: Animal crosses Rs 600 crore club, beats Sam Bahadur | Check day-wise collection

India vs South Africa 1st T20I Free Live Streaming: When and Where to watch IND VS SA T20I series Match LIVE on Mobile Apps, TV, Laptop, Online

US Fed, ECB, Bank of England poised to keep interest rates on hold

NPS (National Pension System): How to create a corpus of Rs 5 crore with Rs 442 investment/day? After retirement, you will get Rs 2.5 lakh every month

MP BJP MLAs to meet on Monday to elect legislative party leader; CM likely to be announced

Manu Ahuja, CEO of Jubilant Agri and Consumer Products, passes away

Seal integrity issue forces Cipla unit to recall one lot of medication in US

Animal Box Office Collection: Ranbir Kapoor-starrer touches Rs 600 crore mark worldwide | Check OTT release details

Vehicle Insurance Policy: If your car drowns during flood or storm, can you claim insurance? Know rules

COVID-19 Update: India records 148 new coronavirus cases, infection tally stands at 4.50 crore

Vishnu Deo Sai to be Chhattisgarh CM; BJP's tribal face whom Shah promised to make a 'big man'

Higher sales of cancer drugs Darzalex and Imbruvica, and psoriasis drug Tremfya helped drive a 17.6 percent rise in pharmaceuticals sales to $9.68 billion, the company said.

High-margin treatments from Actelion, which was acquired by J&J for $30 billion in 2016, accounted for about a quarter of the pharmaceutical unit`s sales growth.

Sales at J&J`s consumer products unit, which makes Band-Aids, Neutrogena beauty products and Tylenol, rose 3.1 percent to $3.5 billion.

The net loss was $10.71 billion, or $3.99 per share, for the latest quarter, compared with a profit of $3.81 billion, or $1.38 per share, a year earlier.

Excluding items, J&J earned $1.74 per share, slightly above the analysts` average estimate of $1.72 per share, according to Thomson Reuters I/B/E/S.

J&J forecast an adjusted profit of $8 to $8.20 per share on revenue of $80.6 billion to $81.4 billion for 2018.

Analysts on average were expecting a profit of $7.87 per share and revenue of $80.7 billion.

Shares of the company were up marginally in premarket trading.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)